Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 1430 pages report, published by Global Markets Direct

Keywords : Glioblastoma Multiforme (GBM) Therapeutic Products under Development, Key Players in Glioblastoma Multiforme (GBM) Therapeutics, Glioblastoma Multiforme (GBM) Pipeline Overview, Glioblastoma Multiforme (GBM) Pipeline, Glioblastoma Multiforme (GBM) Pipeline Assessment

Report ThumbnailJune-2017
Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial cells known as astrocytes. Signs and symptoms include slowly progressive neurologic deficit, usually motor weakness, headache, generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment and seizures. Treatment includes radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 102, 55, 1, 5, 158, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 10, 15, 1, 32 and 9 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
  • List of Tables
  • Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..17), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..18), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..19), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017 (Contd..1), H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Actuate Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Advantagene Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Ambrx Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Apac Biotech Pvt Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by apceth Biopharma GmbH, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Arog Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Athenex Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Autotelic Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Basilea Pharmaceutica Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Batu Biologics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Bayer AG, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Beactica AB, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Berg LLC, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Bio-Path Holdings Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Biomar Microbial Technologies, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Bioncotech Therapeutics SL, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corp, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Cellmid Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corp, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by CLL Pharma SA, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Critical Outcome Technologies Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Cynata Therapeutics Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by CytoVac A/S, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by CytRx Corp, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by DelMar Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by EntreChem SL, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Gene Techno Science Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Genentech Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Genisphere LLC, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by GlioPharma ApS, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by GtreeBNT Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Hamlet Pharma AB, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Hutchison China MediTech Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Immatics Biotechnologies GmbH, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Immune Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Immunomedics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Immunomet Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Immupharma Plc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Incyte Corp, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Innovation Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Inspyr Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Insys Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Ipsen SA, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Juno Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corp LLC, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Lion Biotechnologies Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by MacroGenics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Mateon Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics Corp, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by MedImmune LLC, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Merck KGaA, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Midatech Pharma Plc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by MimiVax LLC, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Moleculin Biotech Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by NanoCarrier Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Nanomerics Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Nektar Therapeutics, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Neonc Technologies Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Neumedicines Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corp, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Novogen Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Nuo Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by NuvOx Pharma LLC, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Omniox Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Oncternal Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Orphit SAS, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co KG, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Ovensa Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Peptomyc SL, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Pharmicell Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Phoenix Biotechnology Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by PIQUR Therapeutics AG, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Plex Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by PTC Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Puma Biotechnology Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by ReNeuron Group Plc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Rgenix Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Richter Gedeon Nyrt, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Sapience Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Scancell Holdings Plc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau SpA, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by SignPath Pharma Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by SOM Biotech SL, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by StemGen SpA, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Sunesis Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Symphogen A/S, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Systimmune Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co KG, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Transgene SA, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Trillium Therapeutics Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Tyme Technologies Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Vault Pharma Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by VCN Biosciences SL, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Vertex Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by X4 Pharmaceuticals Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by Yooyoung Pharm Co Ltd, H1 2017
  • Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology Inc, H1 2017
  • Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017
  • Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Glioblastoma Multiforme (GBM) - Discontinued Products, H1 2017
  • Glioblastoma Multiforme (GBM) - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Table of Contents
  • Table of Contents 2
  • Introduction 10
  • Glioblastoma Multiforme (GBM) - Overview 11
  • Glioblastoma Multiforme (GBM) - Therapeutics Development 12
  • Glioblastoma Multiforme (GBM) - Therapeutics Assessment 57
  • Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 83
  • Glioblastoma Multiforme (GBM) - Drug Profiles 181
  • Glioblastoma Multiforme (GBM) - Dormant Projects 1365
  • Glioblastoma Multiforme (GBM) - Discontinued Products 1375
  • Glioblastoma Multiforme (GBM) - Product Development Milestones 1377
  • Appendix 1388

Please select a license type

Share

Related Products

Global Markets DirectGlioblastoma Multiforme (GBM) - Pipeline Review, H1 2017Product ThumbnailGlioblastoma Multiforme (GBM) - Pipeline Review, H1 2017, Industry ReportProduct #: 829033
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved